Want to see HK:1332 full AI Analyst Report?
China Touyun Tech Group (1332) AI Stock Analysis
China Touyun Tech Group
(HKEX:1332)
The score is driven primarily by severely weak financial fundamentals, including negative equity and poor cash generation. Mixed-to-weak technical indicators add pressure, while the low P/E provides limited support.
China Touyun Tech Group (1332) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 439.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.08M
- Price to Earnings (P/E)
- 2.2
- Beta (1Y)
- -0.16
- Revenue Growth
- -39.50%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 302
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Packaging & Containers
China Touyun Tech Group Business Overview & Revenue Model
Company Description
Touyun Biotech Group Limited functions as a diversified investment holding company, primarily focused on the global design, development, manufacturing, and sale of a wide array of packaging products. Its market presence extends across Hong Kong, the...
China Touyun Tech Group Financial Statement Overview
Summary
Financial performance is distressed: sharply declining revenue, persistent operating losses, deeply negative equity, high leverage, and chronically negative cash flow outweigh the recent net profit.
Income Statement
35NegativeBalance Sheet
15Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.84M | 66.97M | 159.97M | 198.64M | 315.82M | 283.50M |
| Gross Profit | 15.88M | 16.22M | 72.07M | 56.60M | 120.12M | 107.05M |
| EBITDA | -22.65M | -37.97M | -17.19M | -228.57M | -144.39M | -83.13M |
| Net Income | 213.40M | 26.80M | -88.11M | -268.94M | -198.06M | -72.95M |
Balance Sheet | ||||||
| Total Assets | 977.26M | 619.70M | 550.32M | 607.34M | 887.70M | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 4.39M | 5.06M | 69.64M | 36.04M | 144.25M | 93.95M |
| Total Debt | 482.12M | 413.62M | 384.59M | 384.91M | 395.01M | 317.37M |
| Total Liabilities | 644.63M | 592.31M | 590.96M | 586.27M | 604.19M | 537.68M |
| Stockholders Equity | 141.19M | -51.10M | -83.20M | -848.00K | 263.96M | 469.92M |
Cash Flow | ||||||
| Free Cash Flow | -12.85M | -32.60M | -53.54M | -13.49M | -39.30M | -304.60M |
| Operating Cash Flow | -9.45M | -29.64M | -49.87M | 3.65M | -26.37M | -53.81M |
| Investing Cash Flow | -17.60M | -10.80M | -4.66M | -70.95M | -17.25M | -147.74M |
| Financing Cash Flow | 16.28M | 27.32M | 35.74M | -27.68M | 102.63M | 123.17M |
China Touyun Tech Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Neutral. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 48.60 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1332.
China Touyun Tech Group Peers Comparison
Overall Rating
HK:689855Neutral
HK:182045Neutral
HK:829145Neutral- HK:133244Neutral
HK:071641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| HK:6898 | 55Neutral | HKD 692.21M | 28.57 | 12.61% | 0.56% | 19.35% | 53.85% |
| HK:1820 | 45Neutral | HKD 841.77M | -20.91 | -7.47% | 2.86% | 3.70% | -24.49% |
| HK:8291 | 45Neutral | HKD 46.08M | 8.81 | -1.85% | ― | 50.21% | -74.97% |
| HK:1332 | 44Neutral | HKD 439.34M | 2.21 | 473.76% | ― | -39.50% | ― |
| HK:0716 | 41Neutral | HKD 869.51M | 11.35 | 1.77% | 9.59% | -28.18% | -67.44% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1332 | China Touyun Tech Group | 0.15 | -0.35 | -70.00% | |
| HK:0468 | Greatview Aseptic Packaging Company | 2.50 | 0.00 | 0.00% | |
| HK:0716 | Singamas Container Holdings | 0.36 | -0.23 | -39.17% | |
| HK:1820 | Pacific Millennium Packaging Group Corp. | 2.80 | 0.65 | 30.11% | |
| HK:6898 | China Aluminum Cans Holdings Ltd. | 0.72 | -0.01 | -0.69% | |
| HK:8291 | Wan Cheng Metal Packaging Company Limited | 0.22 | -0.01 | -2.26% |
China Touyun Tech Group Corporate Events
Touyun Biotech Sets Liquidity and Growth Measures to Address Going-Concern Audit Disclaimer
Touyun Biotech Group Limited has outlined a series of measures to address a disclaimer of opinion on its going-concern status, primarily by reinforcing its capital base and diversifying revenue sources. The group is launching new health products aime...
Touyun Biotech Grants 74.6 Million Share Options to Director and Staff
Touyun Biotech Group Limited has granted share options under its 2025 Share Option Scheme to one executive director and 22 employees, covering a total of 74,583,800 shares. The options carry an exercise price of HK$0.20 per share, set above recent ma...
Touyun Biotech Raises HK$15 Million via Share Subscription to Fund New Materials Expansion
Touyun Biotech Group Limited has completed a share subscription under its general mandate, issuing 123,000,000 new shares at HK$0.122 each to a new subscriber, raising gross proceeds of HK$15.01 million. The new shares represent about 4.20% of the en...
Touyun Biotech Details HK$15 Million Share Subscription Proceeds
Touyun Biotech Group Limited has clarified the planned use of proceeds from its previously announced subscription of new shares under a general mandate in Hong Kong. The gross funds raised are expected to be about HK$15 million, with net proceeds of...
Touyun Biotech Delivers Strong Interim Profit Surge on Higher Other Income
Touyun Biotech Group Limited reported a sharp increase in unaudited profit for the six months ended 30 June 2026, with total profit rising to HK$310.8 million from HK$28.1 million a year earlier. Earnings attributable to shareholders surged to HK$197...
Touyun Biotech forecasts more than tenfold jump in first-half profit
Touyun Biotech Group Limited has alerted shareholders that it expects to report profit and total comprehensive income attributable to owners of between HK$180 million and HK$200 million for the six months ended 30 June 2026, compared with HK$16 milli...
Touyun Biotech to Raise HK$15 Million via Discounted Share Subscription
Touyun Biotech Group Limited has entered into an agreement with a subscriber to issue 123,000,000 new shares under its existing general mandate. The new shares represent about 4.38% of the current issued share capital and around 4.20% after enlargeme...
Touyun Biotech Sets Board Meeting to Review Interim Results and Dividend
Touyun Biotech Group Limited has scheduled a board meeting for 28 August 2026 in Hong Kong to review and approve its interim results for the six months ended 30 June 2026. The session will also consider the declaration of an interim dividend, signali...
Touyun Biotech appoints new vice chairlady to lead expansion in new materials
Touyun Biotech Group has appointed Ms. Zhou Ruijuan as executive director and vice chairlady, effective 3 August 2026, tasking her with overseeing development of the group’s new materials business. Her appointment signals management’s foc...
Touyun Biotech Clarifies Board and Committee Roles in Governance Update
Touyun Biotech Group Limited has announced the current composition of its board of directors, naming Wang Liang as chairman, Zhou Ruijuan as vice chairlady, and detailing the roles of its executive, non-executive and independent non-executive members...
Touyun Biotech Shifts Registered Office in Bermuda
Touyun Biotech Group Limited has announced that it will change the address of its registered office in Bermuda to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, effective 3 August 2026. The move is largely administrative in nature but may refl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026